Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options
- PMID: 26389761
- DOI: 10.1097/PPO.0000000000000147
Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options
Abstract
Epidermal growth factor receptor (EGFR) mutations define a subset of non-small cell lung cancers that are sensitive to EGFR-targeted tyrosine kinase inhibitors (TKIs). Treatment with EGFR TKIs improves outcomes for patients whose tumors harbor these mutations, but their efficacy is limited by the development of acquired resistance. The secondary gatekeeper mutation, T790M, is the most common resistance mechanism observed in patients who progress on erlotinib and gefitinib, and a new class of drugs has recently been developed to target mutant EGFR and T790M. Here, we review the latest data with each generation of EGFR inhibitors and discuss emerging resistance mechanisms that have been observed in patients who have progressed on the latest class of EGFR TKIs. Looking ahead, combination treatment strategies in the frontline and resistant setting may be required to promote more durable responses and delay the development of resistance, and longitudinal analyses of plasma circulating tumor DNA may allow for earlier detection of emerging resistance mutations.
Similar articles
-
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Lung Cancer. 2016. PMID: 26898616 Review.
-
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613. J Cancer Res Ther. 2016. PMID: 28230005 Review.
-
Emerging treatment for advanced lung cancer with EGFR mutation.Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.
-
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.Lung Cancer. 2015 Sep;89(3):287-93. doi: 10.1016/j.lungcan.2015.06.016. Epub 2015 Jul 2. Lung Cancer. 2015. PMID: 26169499
-
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.Lung Cancer. 2013 Nov;82(2):294-8. doi: 10.1016/j.lungcan.2013.08.023. Epub 2013 Sep 3. Lung Cancer. 2013. PMID: 24035188
Cited by
-
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.Oncotarget. 2016 May 17;7(20):29154-65. doi: 10.18632/oncotarget.8684. Oncotarget. 2016. PMID: 27081078 Free PMC article.
-
A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.Respir Med Case Rep. 2017 Aug 18;22:183-186. doi: 10.1016/j.rmcr.2017.08.015. eCollection 2017. Respir Med Case Rep. 2017. PMID: 28879074 Free PMC article.
-
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.Sci Rep. 2017 Jul 26;7(1):6595. doi: 10.1038/s41598-017-06632-y. Sci Rep. 2017. PMID: 28747773 Free PMC article.
-
Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer.Transl Cancer Res. 2022 May;11(5):1245-1254. doi: 10.21037/tcr-22-970. Transl Cancer Res. 2022. PMID: 35706796 Free PMC article.
-
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance.Cancers (Basel). 2019 Jul 1;11(7):923. doi: 10.3390/cancers11070923. Cancers (Basel). 2019. PMID: 31266248 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
